Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review. by Broderick, P et al.
Accepted Manuscript
Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in
an Analysis of Families and Patients—a Systematic Review
Peter Broderick, Sara E. Dobbins, Daniel Chubb, Ben Kinnersley, Malcolm G.
Dunlop, Ian Tomlinson, Richard S. Houlston
PII: S0016-5085(16)35138-1
DOI: 10.1053/j.gastro.2016.09.041
Reference: YGAST 60735
To appear in: Gastroenterology
Accepted Date: 27 September 2016
Please cite this article as: Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, Tomlinson
I, Houlston RS, Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in
an Analysis of Families and Patients—a Systematic Review, Gastroenterology (2016), doi: 10.1053/
j.gastro.2016.09.041.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Broderick et al  
1 
 
Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of 
Families and Patients—a Systematic Review  
Peter Broderick
1*
, Sara E Dobbins
1*
, Daniel Chubb
1*
, Ben Kinnersley
1
, Malcolm G Dunlop
2
, Ian 
Tomlinson
3
, Richard S Houlston
1,4
 
1. Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, 
UK. 
2. Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, Western 
General Hospital, Edinburgh EH4 2XU 
3. Molecular and Population Genetics Laboratory and NIHR Biomedical Research Centre, 
Oxford Centre for Cancer Gene Research, Wellcome Trust Centre for Human Genetics, 
University of Oxford, Oxford OX3 7BN, UK. 
4. Division of Pathology, The Institute of Cancer Research, London SM2 5NG, UK 
* These authors contributed equally to this work. 
Correspondence to: Richard S Houlston, E-mail: richard.houlston@icr.ac.uk; Tel: +44 (0) 208 722 
4175; Fax: +44 (0) 722 4365.  
 
CONFLICT OF INTEREST 
Peter Broderick, Sara E Dobbins, Daniel Chubb, Ben Kinnersley, Malcolm G Dunlop, Ian Tomlinson, 
Richard S Houlston:  None to declare 
 
ACKNOWLEDGEMENTS 
This work was supported by Cancer Research UK Research (C1298/A8362, Bobby Moore Fund for 
Cancer Research UK) and the European Union (FP7/2007-2013) under Grant No. 258236, FP7 
collaborative project SYSCOL. D.C. was funded by a grant from Bloodwise. Additional support was 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Broderick et al  
2 
 
provided by the National Cancer Research Network and the National Health Service (NHS). In 
Oxford, the work was funded by the Oxford Comprehensive Biomedical Research Centre core 
infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford (Wellcome Trust 
090532/Z/09/Z).  In Scotland, the work was funded by a Cancer Research UK (C348/A12076) and 
Medical Research Council Grant (MR/KO18647/1). This study makes use of the ICR1000 UK exome 
series data generated by Professor Nazneen Rahman’s team at The Institute of Cancer Research, 
London. This work made use of samples generated by the 1958 Birth Cohort.  Access to these 
resources was enabled via the 58READIE Project funded by Wellcome Trust and Medical Research 
Council (grant numbers WT095219MA and G1001799). This publication is supported by COST 
Action BM1206. 
 
AUTHOR CONTRIBUTIONS 
Conception and design: Peter Broderick, Daniel Chubb, Sara E Dobbins, Richard S. Houlston 
Collection and assembly of data: Peter Broderick, Daniel Chubb, Sara E. Dobbins, Malcolm G 
Dunlop, Ian Tomlinson, Richard S. Houlston 
Data analysis and interpretation: Peter Broderick, Daniel Chubb, Ben Kinnersley, Sara E. Dobbins, 
Richard S. Houlston 
Manuscript writing: All authors 
Final approval of manuscript: All authors 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Broderick et al  
3 
 
ABSTRACT 
High-throughput sequencing analysis has accelerated searches for genes associated with risk for 
colorectal cancer (CRC); germline mutations in NTHL1, RPS20, FANCM, FAN1, TP53, BUB1, BUB3, 
LRP6, and PTPN12 have been recently proposed to increase CRC risk. We attempted to validate 
the association between variants in these genes and development of CRC in a systematic review of 
11 publications, using sequence data from 863 familial CRC cases and 1604 individuals without 
CRC (controls). All cases were diagnosed at an age of 55 years or younger and did not carry 
mutations in an established CRC predisposition gene. We found sufficient evidence for NTHL1 to 
be considered a CRC predisposition gene—members of 3 unrelated Dutch families were 
homozygous for inactivating p.Gln90Ter mutations; a Canadian woman with polyposis, CRC, and 
multiple tumors was reported to be heterozygous for the inactivating NTHL1 
p.Gln90Ter/c.709+1G>A mutations; and a man with polyposis was reported to carry 
p.Gln90Ter/p.Gln287Ter; whereas no inactivating homozygous or compound heterozygous 
mutations were detected in controls. Variants that disrupted RPS20 were detected in a Finnish 
family with early-onset CRC (p.Val50SerfsTer23), a 39-year old individual with metachronous CRC 
(p.Leu61GlufsTer11 mutation), and a 41-year-old individual with CRC (missense p.Val54Leu), but 
not in controls. We therefore found published evidence to support the association between 
variants in NTHL1 and RPS20 with CRC, but not of other recently reported CRC susceptibility 
variants. We urge the research community to adopt rigorous statistical and biological approaches 
coupled with independent replication before making claims of pathogenicity. 
 
KEYWORDS 
Colon cancer, inherited, Germline, Exome Sequencing 
 
ARTICLE 
Understanding the genetics of familial CRC is clinically important to discriminate between high- 
and low-risk groups. Mutations in eleven genes are well-established to confer significant increases 
in CRC risk and testing for these is common in clinical practice. Despite this in many CRC families 
no genetic diagnosis can be made. While the availability of high-throughput-sequencing has 
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accelerated searches for new CRC genes there are challenges in assigning pathogenicity to 
identified variants.  
Here we reviewed the data supporting recent assertions that NTHL1, RPS20, FANCM, FAN1, TP53, 
BUB1, BUB3, LRP6, and PTPN12 are CRC susceptibility genes using an evidence-based framework 
(Supplementary-Material)
1-7
. To search for independent evidence of a role in CRC risk we analyzed 
sequencing data on 863 familial CRC cases and 1,604 controls
8
. All cases were diagnosed aged ≤55 
and were mutation-negative for known CRC genes.  
 
Evidence for variation in NTHL1, which like MUTYH performs base-excision-repair (BER), as a cause 
of recessive-CRC has been provided by three unrelated Dutch families homozygous for the rare 
inactivating p.Gln90Ter mutation (Supplementary-Material, Supplementary-Table  1)
6
. The tumor 
mutation spectrum was enriched for C>T transitions, consistent with defective BER. Subsequently 
compound heterozygosity for inactivating NTHL1 p.Gln90Ter/c.709+1G>A mutations was 
identified in a Canadian woman diagnosed with polyposis, CRC and multiple tumors
9
. Tumors were 
again enriched for somatic C>T transitions. While we found no p.Gln90Ter homozygotes amongst 
our WES cases, a 41-year old male case with co-incident polyposis harbored 
p.Gln90Ter/p.Gln287Ter. No inactivating homozygotes or compound heterozygotes were seen 
among our 1,604 controls. 
Whole-exome sequencing (WES) of a Finnish Amsterdam-positive family demonstrated significant 
segregation of RPS20 p.Val50SerfsTer23 with early-onset CRC (LOD score=3.0; Supplementary-
Material, Supplementary-Table 1)
3
. No disruptive RPS20 variants have been catalogued by the 
Exome-Aggregation-Consortium (ExAC), which contains WES data for 60,706 individuals of diverse 
ancestries
10
 suggesting the gene is intolerant to mutation. Hence, it is notable that in our WES 
series we identified the disruptive p.Leu61GlufsTer11 mutation in a 39-year old with 
metachronous CRC.  Furthermore we identified the deleterious missense p.Val54Leu in an 
Amsterdam-positive 41-year old case. No rare missense/disruptive mutations identified in the 
1,604 controls.  
Smith et al. identified FANCM p.Arg1931Ter in two sporadic CRC cases with cancers showing loss 
of the wild-type allele (LOH)
5
. p.Arg1931Ter has been shown to induce exon skipping resulting in 
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decreased DNA-repair (Supplementary-Material, Supplementary-Table  1). In our WES series we 
detected p.Arg1931Ter in four cases and one control (P=0.02; Supplementary-Table 3). To seek 
further evidence for an association between p.Arg1931Ter and CRC, we investigated the frequency 
of this specific variant in two additional UK series totaling 5,552 cases and 6,792 population 
controls (published Illumina-Exome-BeadChip data
11
; Supplementary-Material). Combining these 
data provided no evidence for an association (Meta-analysis P=0.22; Supplementary Figure 1).  
FAN1 mutations have been reported as a cause of CRC in Amsterdam-positive families
4
, but 
evidence for segregation was weak (P=0.125) and the evidence for any functional effect of 
mutation was only shown in non-colonic tissue (Supplementary-Material, Supplementary-Table 1). 
In our WES series we found no significant increase in the burden of FAN1 mutations in cases (Table 
1; Supplementary-Tables 2&3). 
Germline mutation of TP53, archetypically associated with Li-Fraumeni syndrome, has recently 
been suggested to cause familial CRC at a frequency comparable to APC
7
. The assertion was, 
however, based on the flawed assumption that all rare missense changes seen were disease-
causing with no consideration of mutation burden in controls (Supplementary-Material, 
Supplementary-Table 1). In our data no over-representation of TP53 mutation was seen in cases 
(Table 1, Supplementary-Tables 2&3).  
By WES small numbers of early-onset CRC, BUB1, BUB3, LRP6 and PTPN12 have been proposed as 
CRC predisposition genes
1,2
. The published evidence to support assertions is minimal 
(Supplementary-Material, Supplementary-Table 1) with no evidence of segregation or LOH. 
Moreover, of the two BUB1 mutation carriers, one also carried a MLH1 mutation which, unlike 
BUB1, segregated with colorectal tumors. Only for PTPN12 did the authors demonstrate an 
increase in the burden of mutation in cases versus controls (P=0.039; Supplementary-Material). 
While we also observed an enrichment of missense PTPN12 mutation in our WES cases (P=0.039; 
Table 1, Supplementary-Table 3), in light of the number of genes investigated, the evidence for a 
role in CRC predisposition remains weak.  
In conclusion a role for NTHL1 as a bona fide CRC gene is supported by multiple lines of evidence. 
While compelling, the assertion that mutation of RPS20 causes CRC remains to be established as 
this observation is based on a single family and the mechanism by which ribosomal proteins might 
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predispose to CRC is unclear. In contrast, evidence to support other genes as risk factors is 
currently lacking.  
Investigators must remember that private variants are common; of the 7,404,909 variants listed in 
ExAC, 54% are observed only once
10
, therefore novel variants should be considered benign until 
proved otherwise. A studies power to detect a statistically significant association with any rare 
variant is typically weak, therefore additional evidence must be considered including segregation 
of the genotype with disease in families, somatic mutation and functional studies with relevance 
to CRC biology. Critically, where multiple variants are considered within a gene, the burden of 
variation within controls must also be considered. Since the frequency of variants can be highly 
population-specific it is essential that controls used for comparison are well matched. 
 
While there is a strong rationale for seeking to identify new CRC genes, well powered studies are 
required to mitigate against erroneous findings being asserted as causative and subsequently 
included in databases from which they are seldom deleted. The WES data we have generated 
represents the largest cohort of CRC exomes sequenced to date. The use of this dataset, which is 
publically available, to validate observations from small sequencing studies should act to limit the 
reporting of false positive results. Finally, the evidence framework we have implemented to assess 
the validity of proposed CRC genes, provides a robust strategy for establishing clinically actionable 
genes. 
 
 
 
 
TABLES AND FIGURES 
Table 1: Gene Burden analysis. Number of cases (n=863) and controls (n=1,604) with rare 
(MAF<1%) mutations in postulated CRC genes. P-values calculated using Fishers exact test, P-
values <0.05 are emboldened.   
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Table 1:  Gene Burden analysis. Number of cases (n=863) and controls (n=1,604) with rare (MAF<1%) mutations in postulated CRC genes. P-
values calculated using Fishers exact test, P-values <0.05 are emboldened.  
 
  
Disruptive mutations 
(stop-gain, frameshift) 
Damaging mutations 
(disruptive, predicted-damaging, splice 
acceptor/donors 
All coding non-synonymous variants 
Gene Previously Reported Cases Control PFisher Cases Control PFisher Cases Control PFisher 
           
BUB1 Disruptive 0 4 0.31 1 8 0.17 18 30 0.76 
BUB3 Missense 0 2 0.55 0 4 0.31 1 5 0.67 
FAN1 Disruptive /Missense 0 2 0.55 15 17 0.19 32 45
#
 0.23 
FANCM Disruptive /Missense 5 1 0.02 23 33 0.33 51
$
 67
$
 0.06 
LRP6 (BPD*) Missense 0 0 - 6 (4) 17 (13) 0.51 (0.45) 17 (8) 37 (21) 0.67 
PTPN12 Missense 0 1 1.00 6 5 0.21 12 9 0.04 
RPS20 Disruptive 1 0 0.35 2 0 0.12 2 0 0.12 
TP53 Missense 1 0 0.35 1 1 1.00 1 4 0.66 
           
 
* Number of variants within β-Propellor domain.  All 3 variants identified by de Voer et al were within BPD.  
# Total number of variants in controls = 46; 1 sample has 2 FAN1 missense 
$ Totals number of variants in cases = 52, in controls =69; 3 samples have 2 FANCM missense 
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SUPPLEMENTARY METHODS AND MATERIALS  
 
METHODS 
INDEPENDENT EVALUATION 
Whole-exome sequencing data: To search for independent evidence and to contextualize 
the impact of each purported CRC gene we made use of recently published whole-exome 
sequencing (WES) data on 1,006 early-onset familial CRC cases and 1,609 healthy controls
1
. 
Cases were of European Ancestry recruited to the UK National Study of Colorectal Cancer 
Genetics (NSCCG)
2
. All cases were diagnosed with CRC aged ≤55 and had at least one first-
degree relative diagnosed with CRC. Controls were individuals with no history of malignancy 
selected from the 1958 Birth Cohort (1958BC), a longitudinal study following the lives of 
people born in England, Scotland and Wales during the week of 3-9 March 1958
3
. Full details 
of WES have been published previously. Briefly, paired end fastq files were aligned to build 
37 (hg19) of the human reference genome and alignments were processed using the 
Genome Analysis Tool Kit (GATKv3) pipeline according to best practices
4
. The Variant Effect 
Predictor
5
 was used to provide annotations on the predicted impact of each variant 
together with functional classifications and assessment of deleteriousness from the 
CONDEL
6
 algorithm. Samples (cases and controls) with a variant in an established high-
penetrance CRC gene which was predicted to be disruptive (stop-gain, frameshift) or 
previously catalogued as being pathogenic or likely-pathogenic by InSiGHT (The 
International Society for Gastrointestinal Hereditary Tumours) were removed. Specifically: 
APC: 19 cases, 1 control; MLH1: 46 cases; MSH2: 46 cases; MSH6: 13 cases, 1 control; 
MUTYH: 9 cases; PMS2: 6 cases, 2 controls; POLD1: 1 case, 1 control; POLE: 3 cases; 
BMPR1A, SMAD4, STK11: 0 cases.  Thus for the analysis presented in this manuscript we 
made use of whole-exome sequencing data on 863 cases and 1,604 controls. 
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Gene Burden Analysis: With currently attainable sample sizes, a studies power to detect a 
statistically significant association with any rare variant is typically weak. Here we use WES 
data described above, to look for an enrichment of variation in cases versus controls, for 
each postulated CRC gene as a whole. As the power of such comparison depends critically 
on the ability to distinguish between pathogenic and non-pathogenic variation, we defined 
and compared a number of variant classes: (1) Disruptive mutations (stop-gain, frameshift); 
(2) Disruptive and predicted damaging mutations (stop-gain, frameshift, missense predicted 
to be damaging by CONDEL, splice site acceptor/donors); (3) All coding non-synonymous 
variants. We assessed rare (minor allele frequency [MAF] <1%) and very rare (MAF<0.1%) 
mutations in each variant class. Comparisons were made using (a) all 863 cases (b) 159 cases 
with Amsterdam-II positive family histories (Amsterdam-I n=146). Thus in total we 
performed 12 comparisons for each gene. 
 
Further analysis of the recurrent FANCM p.Arg1931Ter (rs144567652) variant: We studied 
the association of the recurrent variant FANCM p.Arg1931Ter (rs144567652) with CRC by 
analyzing published Illumina Infinium Human Exome BeadChip 12v1.0 or 12v1.1 exon array 
data
7
. Specifically, we made use of UK case/control data (excluding samples also included in 
our WES data) comprising: (i) 3,537 English CRC cases and 4,811 control patients; (ii) 2,015 
Scottish CRC cases and 1,981 Scottish controls.  
 
EVIDENCE FRAMEWORK 
To assess the validity of purported CRC genes, accounting for varying study design, we 
collated the following evidence where appropriate (Supplementary Table 1):  
(1) Where gene/variants were identified through the analysis of multiple members of a 
single family we evaluated the strength of segregation data – co-inheritance of the 
mutation with affection status (CRC or polyps) in the family. If not formally 
quantified in the published report we calculated non-parametric linkage (NPL) 
statistic P-values
8
 using the family information provided.  
(2) Where a specific CRC risk variant was reported: we looked for reported evidence of a 
statistically significant enrichment in CRC cases versus controls. In conjunction with 
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our WES data we examined frequency data on the mutation in an ethnically 
appropriate subset of the Exome-Aggregation-Consortium (ExAC) database
9
; a 
catalog of exome sequencing data for 60,706 individuals of diverse ancestries (non-
Finnish European (NFE) 33,370 exomes, East Asian (EAS) 4,327 exomes, Finnish (FIN) 
3,307 exomes). 
(3) Where numerous variants are identified in a specific gene: we looked for evidence of 
gene burden testing in cases versus controls, and if performed, evidence of 
statistically significant enrichment of mutation in cases. 
(4) Where recessive inheritance was suspected or indicated: homozygosity or 
compound-heterozgosity for pathogenic mutations in the proposed CRC gene was 
assessed in cases and controls. 
(5) Computational data on the presumptive effect of the variant. 
(6) Functional data – demonstration that mutation has a functional effect and the 
relevance to CRC biology. 
(7) Other information – evidence of a highly-specific phenotype associated with CRC, 
evidence of somatic mutation of the wild-type allele in cancers from carriers 
consistent with tumor suppressor gene function.  
 
REVIEW OF EXISTING LITERATURE FOR EACH GENE ASSESSED 
NTHL1 
Evidence for variation in NTHL1 as a cause of recessive CRC has been provided by three 
unrelated Dutch families homozygous for the rare (ExAC NFE MAF=0.0023, homozygosity 
~1/75,000) inactivating p.Gln90Ter mutation
10
. Multiple colorectal adenomas with or 
without CRC were diagnosed in all seven homozygotes. The tumor mutation spectrum was 
significantly enriched for C:G>T:A transitions, consistent with the mutation spectra observed 
in NTHL1 double-knockout mice. Subsequent to this report, compound heterozygosity for 
inactivating NTHL1 p.Gln90Ter/c.709+1G>A mutations was identified in a 41-year old 
Canadian woman diagnosed with polyposis, CRC and multiple tumors
11
. Tumors were again 
enriched for somatic C:G>T:A transitions. 
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Evidence Summary: Multiple reports associating homozygosity and compound-
heterozygosity with CRC. Evidence of functional effect in CRC. 
 
RPS20 
In seven affected members (average age 52, range 24-75) of a four-generation Finnish 
Amsterdam-positive FCCTX family, Nieminen et al. identified a heterozygous 1-bp 
duplication, resulting in a frameshift and premature termination (p.Val50SerfsTer23), in 
RPS20
12
. The mutation, identified through genetic linkage analysis and WES, showed full co-
segregation with microsatellite-stable early-onset CRC thus providing statistically significant 
evidence (reported LOD score=3.0; calculated NPL=5.35, P=0.0078) for germline mutation in 
RPS20 as a cause of CRC. The mutation was absent in 292 population controls and is not 
reported in the ExAC database, which includes 3,307 Finnish individuals. Tumors from 
mutation carriers did not show loss of the wildtype allele (LOH
WT
). Lymphoblastoid cells 
(LCLs) from cases carrying p.Val50SerfsTer23 mutation showed a marked increase in 21S 
pre-rRNAs compared to controls (P-value not calculated), consistent with a late pre-rRNA 
processing defect and suggestive of RPS20 haploinsufficiency. Germline RPS20 mutations 
were not found in 25 additional Finnish FCCTX families, 292 population controls or in tumor 
DNA from 50 primary CRC and 11 CRC cell lines. 
Evidence Summary: Statistically significant evidence of segregation, absence of gene 
mutation in controls. Functional evidence in non-colon tissue. No evidence of somatic 
mutation or functional effect in CRC. 
 
FANCM 
By searching within tumorigenesis genes for rare/novel truncating mutations, which also 
showed LOH
WT
 within the tumor, Smith et al. identified the FANCM mutation p.Arg1931Ter 
(rs144567652) in one of 50 sporadic UK CRC cases
13
. As FANCM is functionally linked to 
MSH2/MSH6 they sought further evidence for the role of this variant by genotyping an 
additional case-control series identifying the mutation in 1 of 2,207 CRC cases and 1 of 2,176 
controls.  The tumor of the additional case again showed LOH
WT
. Combining discovery and 
replication samples showed no significant enrichment of the mutation in CRC (cases 
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2/2,257, controls 1/2,176, P=0.57). Smith et al. presented no segregation or functional data. 
However, a subsequent report by Peterlongo et al. proposing p.Arg1931Ter as a familial 
breast cancer risk factor showed that p.Arg1931Ter induces exon skipping resulting in 
decreased DNA repair activity in mouse embryonic fibroblast cells
14
.  
Evidence Summary: Loss of wild-type allele in tumors. Functional evidence in non-colon 
tissue. No evidence of segregation or functional effect in CRC. No significant enrichment of 
the mutation in CRC. 
 
FAN1 
Through WES of three individuals from a Spanish MMR-proficient, Amsterdam-positive CRC 
family Sequi et al. identified a novel FAN1 truncating mutation p.Cys47Ter
15
. Evidence of 
segregation with CRC was limited (calculated NPL=0.95, P=0.25). Tumors developed by 
p.Cys47Ter mutation carrier showed no reduction in the expression of wild-type RNA or 
FAN1 protein. Screening an additional 247 Spanish Amsterdam/Bethesda positive cases for 
rare (MAF<0.01; dbSNP135) variants identified an additional truncating mutation 
(p.Arg952Ter) and three missense mutations (p.Asp140Thr and p.Arg591Trp - predicted to 
be damaging by SIFT and CONDEL algorithms; p.Pro340Ser - predicted to be benign). No 
FAN1 mutations were identified in 250 population individuals without CRC. Whilst 
suggestive of an enrichment in cases for the overall burden of variation in FAN1, the size of 
the control population is insufficient to provide statistically robust support (combined 5/248 
cases, 0/250 controls, P=0.061). Using all five families the calculated NPL segregation score 
was non-significant (NPL=1.05, P= 0.125, Supplementary Table 1). There was no evidence of 
FAN1 LOH or somatic mutation in tumors from any of the five FAN1 mutation carriers. LCLs 
derived from p.Cys47Ter and p.Asp140Thr carriers showed greater sensitivity to high doses 
of mitomycin C (MMC) compared to cells from a wild-type individual (p.Cys47Ter: P=0.01 
Wilcoxon rank sum test; p.Asp140Thr: P-value not calculated). Transfection of a FAN1 
knockout human embryonic kidney cell line with p.Asp140Thr failed to reverse its MMC 
sensitivity.   
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Evidence Summary: Limited evidence of segregation and an increase in mutational burden 
in cases. Functional evidence for 2/4 mutations in non-colon tissue. No evidence of somatic 
mutation, LOH or functional effect in CRC. 
 
TP53 
Yurgelun et al. examined the frequency of rare germline TP53 missense mutations in 457 
patients with early-onset CRC (median age 36, range 15-40) and without a known hereditary 
cancer syndrome
16
. In six of the patients (1.3%), they identified missense changes in TP53. 
No comparison was made to the burden of TP53 mutations in controls.  
Based on this data they concluded that the frequency of TP53 mutations is comparable with 
the proportion of inherited CRC thought to be attributable to germline APC mutations.  This 
is a false comparison:  
(1) TP53 missense variant are assumed to be deleterious. However, of the six variants 
they identified only one was predicted to be damaging by both SIFT and PolyPhen-2, 
with three being predicted benign by both algorithms. There was no other evidence 
that mutations had deleterious functional effect.  
(2) The proportion of inherited CRC thought to be attributable to germline APC 
mutations (1%) is not the same as the frequency of samples with APC missense 
changes (in our original 1,006 cases, not screened for mutations in known genes, 94 
[9.3%] had rare [MAF<1%] missense changes in APC). 
Evidence Summary: No comparison was made to mutational burden in controls. No 
evidence (even in silico) mutations have functional effect. No evidence of segregation or 
somatic mutation in CRC.  
 
BUB1 and BUB3 
BUB1: Disruptive mutations (p.Gln16Ter, p.Gln949Argfs) were identified in two of 23 
Chinese early-onset (age at diagnosis ≤45) CRC cases; both variants were absent from 700 
population controls but no comparison was made with the burden of mutations in 
controls
17
. No evidence of segregation was demonstrated and notably one of the mutation 
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carriers harbored a MLH1 mutation (InSiGHT Class4: likely pathogenic), which unlike the 
BUB1 variant was also carried by a sibling with polyps. The functional effect of mutations, 
LOH or somatic mutation within tumors was not assessed. No BUB1 mutations were 
identified among 184 Netherlands/German cases. 
Evidence Summary: Absence of identified mutations in controls, but no comparison made 
to mutational burden in controls. No functional evidence. No evidence of segregation or 
somatic mutation in CRC.  
 
BUB3: WES identified a novel damaging (as predicted by PolyPhen-2 SIFT, HOPE) missense 
mutation (p.Phe264Leu) in one of 10 Dutch early-onset (age at diagnosis ≤45) CRC cases 
(0/23 Chinese cases)
17
. Sequencing BUB3 in 174 Netherlands/German CRC cases identified 
two further missense variants (p.Lys21Asn, p.Arg149Gln) that were predicted (by at least 
one algorithm) to be damaging, although PolyPhen-2 and SIFT predicted p.Arg149Gln to be 
benign. All three variants were absent in 1,154 controls but no comparison was made with 
burden of mutations in controls. No evidence of segregation, LOH or somatic mutation. 
Lymphocytes and primary skin fibroblasts from p.Phe264Leu and p.Lys21Asn mutation 
carriers showed significant enrichment of aneuploidy and structural abnormalities versus 
controls (p.Arg149Gln was not assessed/presented).  
Evidence Summary: Absence of identified mutations in controls, but no comparison made 
to mutational burden in controls. Functional evidence in non-colon tissue. No evidence of 
somatic mutation, LOH or functional effect in CRC. 
 
LRP6 and PTPN12 
Using WES de Voer et al. looked for genes recurrently affected by damaging missense 
mutations, assessed using a single prediction algorithm PhyloP, in 55 Dutch non-polyposis 
MMR-proficient early-onset (age at diagnosis ≤45) CRC cases
18
: 
 
LRP6: Damaging LRP6 missense mutations (p.Trp239Leu, p.Asn789Ser, p.Thr867Ala) were 
identified in three cases. All three variants were within β-propeller domains. In mutation 
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carriers LRP6 protein showed no difference in protein expression or subcellular localization 
compared to wild-type. In Chinese Hamster Ovary cells p.Asn789Ser and p.Thr867Ala 
induced significant increases in WNT signaling activity (P<0.001). Analysis of 174 additional 
Netherlands/German CRC and 2,329 population controls identified no additional damaging 
missense mutations in cases, with 18 identified in controls including p.Thr867Ala in three 
controls. By using only the 55 original cases and the 2,329 controls, de Voer et al. reported 
significant increase in mutation burden in cases versus controls (cases 3/55, controls 
18/2,329, P =0.01). However using all cases there was no significant enrichment of LRP6 
mutation in cases versus controls (cases 3/229, controls 18/2,329, P=0.43).  
Evidence Summary: No increase in mutational burden in cases. Functional evidence in non-
colon tissue. No evidence of somatic mutation, LOH or functional effect in CRC. 
 
PTPN12: WES identified two damaging missense mutations (p.Arg522Met, p.Ser684Leu) in 
three of the 55 cases. Analysis of 174 additional Netherlands/German CRC and 2,329 
population controls identified a new variant (p.Ala105Val) in one case and 11 variants in 
controls including previously identified p.Arg522Met in two controls and p.Ser684Leu in 
three controls. The burden of mutation is cases was significantly enriched versus controls 
(cases 4/229, controls 11/2329, P=0.039) albeit non-significant after adjustment for multiple 
testing (three candidate genes, P=0.12).  
Evidence Summary: Limited evidence of an increase in mutational burden in cases. Variants 
not absent from controls. No evidence of somatic mutation, LOH or functional effect in CRC. 
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SUPPLEMENTARY FIGURES AND TABLES 
Supplementary Figure 1: Forest plot of allelic odds ratio associated with FANCM 
p.Arg1931Ter (rs144567652) genotype and CRC.  Studies [SMITH: original publication (2,207 
cases, 2,176 controls)
13
; WES: whole-exome sequencing analyzed in this manuscript (863 
cases, 1,604 controls); ENG: English Illumina Exome-BeadChip replication series (3,537 
cases, 4,811 controls); SCOT: Scottish Illumina Exome-BeadChip replication series (2,015 
cases, 1,981 controls)] were weighted according to the inverse of the variance of the log of 
the odds ratio (OR) calculated by unconditional logistic regression. Meta-analysis under a 
fixed-effects model was conducted using standard methods. Cochran’s Q statistic to test for 
heterogeneity and the I
2
 statistic to quantify the proportion of the total variation due to 
heterogeneity were calculated. Horizontal lines indicate 95% confidence intervals (CIs). 
Boxes indicate OR point estimate; its area is proportional to the weight of the study. 
Diamond (and broken line) indicates overall summary estimate, with CI given by its width. 
Unbroken vertical line indicates null value (OR=1.0). 
 
Supplementary Table 1: Evidence for genes and variants being associated with CRC risk.  
Analysis of the evidence presented in publications linking NTHL1, RPS20, FANCM, FAN1, 
TP53, BUB1, BUB3, LRP6 and PTPN12 with the risk of developing CRC 
Abbreviations: AOD: Age of CRC diagnosis; EAS: East Asian; FCCTX: Familial CRC Cancer Type X; FS: frameshift; 
Het: heterozygous; Hom: homozygous; LOH: loss of heterozygosity; MMC: Mitomycin C; MS: missense; MSS: 
lack of mismatch repair deficiency (MMR) tested through either microsatellite stability or no loss of MMR 
proteins; NFE: Non-Finnish European; NPL: non-parametric linkage; NT: Not tested; SG: stop-gain; TS: target 
sequencing; WES: whole exome sequencing; WT: wild-type 
 
Supplementary Table 2: Gene Burden analysis. Number of WES cases (n=863) and controls 
(n=1,604) with rare mutations in genes suggested to increase CRC risk. We considered three 
sets of variants: Class-1, disruptive mutations -stop-gain, frameshift; Class-2, predicted 
damaging -disruptive plus missense predicted to be damaging by CONDEL and splice site 
acceptor/donors; Class-3, all coding non-synonymous variants. Tables show -A all cases -
n=863 and controls -n=1,604 with very rare -MAF<0.1% mutations; -B Amsterdam-II positive 
cases -n=159 and controls with rare -MAF<1% mutations; -C Amsterdam-II positive cases 
and controls with very rare -MAF<0.1% mutations. For each gene and variant class, numbers 
of cases and controls were compared and P-values calculated using Fishers exact test. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
Supplementary Table 3: BUB1, BUB3, FAN1, FANCM, LRP6, PTPN12, RPS20 and TP53 
variants -MAF<1% identified in 863 CRC cases and 1,604 controls. -See excel file 
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Supplementary Table 1: Evidence for genes and variants being associated with CRC risk.  Analysis of the evidence presented in publications linking NTHL1, 
RPS20, FANCM, FAN1, TP53, BUB1, BUB3, LRP6 and PTPN12 with the risk of developing CRC 
Abbreviations: AOD: Age of CRC diagnosis; EAS: East Asian; FCCTX: Familial CRC Cancer Type X; FS: frameshift; Het: heterozygous; Hom: homozygous; LOH: loss of heterozygosity; MMC: 
Mitomycin C; MS: missense; MSS: lack of mismatch repair deficiency (MMR) tested through either microsatellite stability or no loss of MMR proteins; NFE: Non-Finnish European; NPL: non-
parametric linkage; NT: Not tested; SG: stop-gain; TS: target sequencing; WES: whole exome sequencing; WT: wild-type 
Gene CRC Gene 
Burden 
Control 
Gene 
Burden 
Gene Functional Data Chr Position 
(GRCh37) 
c.DNA 
Change 
Protein 
Change 
Class dbSNP Segregation Variant Case 
Frequency 
Variant 
Control 
Frequency 
ExAC  
Allele 
Frequency 
Other Information 
NTHL1 WES Hom 3/51 
APC-MUTYH 
mutation-
negative 
polyposis 
patients 
17 Het/ 
2329 
  16 2096239 c.268C>T p.Gln90Ter SG rs1507
66139 
Family1:2/2 
Family2:3/3 
Family3:2/2 
  17 Het/ 
2329 
NFE: 0.0023 Tumors significantly 
enriched for C:G>T:A 
transitions 
RPS20 WES 4 
individuals 
Finnish FCCTX 
family; TS 0/25 
Finnish FCCTX 
NT RPS20 depletion in HeLA 
cells and LCLs from 
patients carrying 
c.147dupA showed 
increase in 21S pre-rRNA 
vs controls 
8 56986283 c.147dupA Val50Serfs 
Ter23 
FS   NPL=5.35,  
P =0.0078 
1/26 FCCTX 
Family 
0/584 Absent No LOH (0/2) 
FANCM WES 1/50 NT   14 45667921 c.5791C>T p.Arg1931Ter SG rs1445
67652 
NT 2/2,258 1/2176 NFE: 0.0009 LOH WT 2/2 
FAN1 WES 3 
individuals 
Spanish FCCTX 
family. TS 4/247 
Spanish FCCTX 
cases 
0/250 LCL from p.C47Ter and 
p.Asp140Tyr carriers 
showed greater sensitivity 
to high doses of MMC. 
Transfection of HEK293T 
(Human Embryonic 
Kidney) FAN1 with 
p.Asp140Tyr failed to 
reverse its MMC 
sensitivity 
15 31197007 c.141C>A p.Cys47Ter SG rs1444
69584 
NPL=0.94,  
P =0.25 
1/248 FCXX 
Family 
0/538 Absent No LOH/somatic 
mutation. No 
reduction in FAN1 
RNA or protein.  
15 31197284 c.418G>T p.Asp140Tyr MS rs7617
76412 
P/C, NPL=0,  
P =1 
1/248 FCXX 
Family 
0/250 NFE: 1.50E-5 Predicted to be 
damaging by 
SIFT/CONDEL. No 
LOH/somatic 
mutation.  
15 31197884 c.1018C>T p.Pro340Ser MS rs7712
06220 
NPL=1.05,  
P =0.125 
1/248 FCXX 
Family 
0/250 NFE: 1.50E-5 Predicted to be 
benign by 
SIFT/CONDEL 
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Gene CRC Gene 
Burden 
Control 
Gene 
Burden 
Gene Functional Data Chr Position 
(GRCh37) 
c.DNA 
Change 
Protein 
Change 
Class dbSNP Segregation Variant Case 
Frequency 
Variant 
Control 
Frequency 
ExAC  
Allele 
Frequency 
Other Information 
FAN1 
(cont’d)    
15 31206254 c.1771C>T p.Arg591Trp MS rs3774
18523 
NT 1/248 FCXX 
Family 
0/250 NFE: 1.50E-5 Predicted to be 
damaging by 
PolyPhen-
2/SIFT/CONDEL 
15 31222812 c.2854C>T p.Arg952Ter SG rs1847
45027 
NPL=0.70,  
P =0.25 
1/248 FCXX 
Family 
0/250 NFE: 9.02E-5   
TP53 TS 6/457 North-
American, 
Australian, New 
Zealand non-
polyposis, 
AOD≤40 
NT   17 7572973 c.1136G>A p.Arg379His MS   NT 1/457 NT Absent Predicted to be 
benign by PolyPhen-
2/SIFT 
17 7577069 c.869G>A p.Arg290His MS rs5581
9519 
NT 1/457 NT NFE: 0.0002 Predicted to be 
benign by PolyPhen-
2/SIFT 
17 7577088 c.850A>T p.Thr284Ser MS s14434
0710 
NT 1/457 NT Absent Predicted to be 
possibly damaging by 
PolyPhen-2, benign 
by SIFT 
17 7577091 c.847C>T p.Arg283Cys MS rs1496
33775 
NT 1/457 NT NFE: 0.0002 Predicted to be 
benign by PolyPhen-
2, possibly damaging 
by SIFT 
17 7577577 c.704A>G p.Asn235Ser MS rs1443
40710 
NT 1/457 NT NFE: 0.0003 Predicted to be 
benign by PolyPhen-
2/SIFT 
17 7578475 c.455C>T p.Pro152Leu MS rs5877
82705 
NT 1/457 NT NFE: 4.50E-5 Predicted to be 
damaging by 
PolyPhen-2/SIFT 
BUB1 WES 2/23 Han 
Chinese ≤40; 
WES 0/10 Dutch 
non-polyposis 
MSS ≤40; TS 
0/174 non-
polyposis MSS 
Dutch/German 
CRC 
NT Disruption of BUB1 exon 1 
in HCT- 116 (MSI human 
CRC) caused chromosomal 
segregation defects 
2 111398721 c.2844delC pGln949Argfs FS   NT 1/23 
Chinese;  
0/184 
European 
0/700 Absent   
2 111431923 c.46C>T p.Gln16Ter SG   No 1/23 
Chinese;  
0/184 
European 
0/700 Absent Carries MLH1 splice 
donor mutation 
which segregates 
with colorectal 
tumors 
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Gene CRC Gene 
Burden 
Control 
Gene 
Burden 
Gene Functional Data Chr Position 
(GRCh37) 
c.DNA 
Change 
Protein 
Change 
Class dbSNP Segregation Variant Case 
Frequency 
Variant 
Control 
Frequency 
ExAC  
Allele 
Frequency 
Other Information 
BUB3 WES 0/23 Han 
Chinese ≤40; WES 
1/10 Dutch non-
polyposis MSS 
≤40; TS 2/174 
non-polyposis 
MSS 
Dutch/German 
CRC 
NT   10 124914496 c.63G>C pLys21Asn MS   NT 0/23 
Chinese;  
1/184 
European 
0/1154   Predicted to be 
damaging by  
PolyPhen-
2/SIFT/HOPE 
10 124919951 c.446G>A Arg149Gln MS rs3715
45161 
NT 0/23 
Chinese;  
1/184 
European 
0/1154 NFE: 7.52E-5 
EAS: Absent 
Predicted to be 
damaging by  HOPE, 
benign by PolyPhen-
2/SIFT/HOPE 
10 124922163 c.790T>C p.Phe264Leu MS   NT 0/23 
Chinese;  
1/184 
European 
0/1154 Absent Predicted to be 
damaging by  
PolyPhen-
2/SIFT/HOPE 
LRP6 WES 3/55 Dutch 
non-polyposis 
MSS AOD≤45; TS 
0/174 non-
polyposis MSS 
Dutch/German 
CRC 
18/ 
2,329 
In Chinese Hamster 
Ovary cells: no effect on 
LRP6 protein expression 
or localization; 
overexpression of 
p.Asn789Ser and 
p.Thr867Ala induced 
increased WNT 
signaling vs WT 
12 12311955 c.2599A>G p.Thr867Ala MS rs1414
58215 
NT WES: 1/55;  
TS: 0/174  
3/2329 NFE: 0.0002 Predicted to be 
damaging by PhyloP 
12 12312812 c.2366A>G p.Asn789Ser MS   NT WES: 1/55; 
TS: 0/174 
0/2329 Absent Predicted to be 
damaging by PhyloP 
12 12339985 c.716G>T p.Trp239Leu MS   NT WES: 1/55; 
TS: 0/174 
0/2329 Absent Predicted to be 
damaging by PhyloP 
PTPN12 WES 3/55 Dutch 
non-polyposis 
MSS ≤45; TS 1/174 
non-polyposis 
MSS 
Dutch/German 
CRC 
11/ 
2,329 
  7 77212900 c.314C>T p.Ala105Val MS   NT WES: 0/55;  
TS: 1/174 
0/2329 Absent Predicted to be 
damaging by PhyloP 
7 77256561 c.1565G>T p.Arg522Met MS rs5375
62368 
NT WES: 1/55; 
TS: 0/174 
2/2329 NFE: 1.50E-5 Predicted to be 
damaging by PhyloP 
7 77261719 c.2051C>T p.Ser684Leu MS rs2010
01953 
NT WES: 2/55; 
TS: 0/174 
3/2329 NFE: 0.0012 Predicted to be 
damaging by PhyloP 
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Supplementary Table 2: Gene Burden analysis. Number of WES cases (n=863) and controls 
(n=1,604) with rare mutations in genes suggested to increase CRC risk. We considered three 
sets of variants: Class-1, disruptive mutations -stop-gain, frameshift; Class-2, predicted 
damaging -disruptive plus missense predicted to be damaging by CONDEL and splice site 
acceptor/donors; Class-3, all coding non-synonymous variants. Tables show -A all cases -
n=863 and controls -n=1,604 with very rare -MAF<0.1% mutations; -B Amsterdam-II positive 
cases -n=159 and controls with rare -MAF<1% mutations; -C Amsterdam-II positive cases 
and controls with very rare -MAF<0.1% mutations. For each gene and variant class, numbers 
of cases and controls were compared and P-values calculated using Fishers exact test. 
 
A  
 
*Number of variants within β-Propellor domain 
# Total number of variants in controls = 11; 1 sample has 2 FAN1 missense  
$ Total number of variants in cases = 15; 1 sample has 2 FANCM missense 
 
B 
  Class-1  Class-2 Class-3 
Gene Cases Controls PFisher Case Control PFisher Case Control PFisher 
BUB1 0 4 1.00 1 8 0.58 4 30 0.54 
BUB3 0 2 1.00 0 4 1.00 0 5 1.00 
FAN1 0 2 1.00 2 17 0.69 6 45 0.46 
FANCM 0 1 1.00 1 33 0.36 7
$
 67
$
 0.84 
LRP6 -BPD* 0 0 - 1 -1 17 -13 1.00 2 -2 37 -21 0.57 
PTPN12 0 1 1.00 1 5 0.44 3 9 0.09 
RPS20 0 0 - 1 0 0.09 1 0 0.09 
TP53 0 0 - 0 1 1.00 0 4 1.00 
 
*Number of variants within β-Propellor domain 
$ Total number of variants in cases = 8 in controls = 69; 3 samples have 2 FANCM missense 
 
  Class-1  Class-2 Class-3 
Gene Cases Controls PFisher Cases Controls PFisher Cases Controls PFisher 
BUB1 0 4 0.31 1 8 0.17 5 16 0.36 
BUB3 0 2 0.55 0 4 0.31 1 5 0.67 
FAN1 0 2 0.55 3 5 1.00 7 10
#
 0.62 
FANCM 1 0 0.35 7 8 0.42 14
$
 21 0.59 
LRP6 -BPD* 0 0 - 3 -1 9 -6 0.56 8 -2 20 -11 0.55 
PTPN12 0 1 1.00 3 3 0.43 8 7 0.17 
RPS20 1 0 0.35 2 0 0.12 2 0 0.12 
TP53 1 0 0.35 1 1 1.00 1 3 1.00 
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C 
  Class-1  Class-2 Class-3 
Gene Cases Controls PFisher Cases Controls PFisher Cases Controls PFisher 
BUB1 0 4 1.00 1 8 0.58 1 16 1.00 
BUB3 0 2 1.00 0 4 1.00 0 5 1.00 
FAN1 0 2 1.00 0 5 1.00 2 10 0.30 
FANCM 0 0 - 0 8 1.00 2
$
 21 1.00 
LRP6 -BPD* 0 0 - 0 9 -6 1.00 0 20 -11 0.25 
PTPN12 0 1 1.00 0 3 1.00 1 7 0.53 
RPS20 0 0 - 1 0 0.09 1 0 0.09 
TP53 0 0 - 0 1 1.00 0 3 1.00 
 
*Number of variants within β-Propellor domain 
$ Total number of variants in cases = 3; 1 sample has 2 FANCM missense 
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Gene Chr Position (GRCh37) Ref Alt CONSEQUENCE Class c.DNA Change Protein Change Control_MAF Case_MAF ALT_Control ALT_Cases ALT_Ams ExAC_Freq ExAC_NFE 1000G_ALL 1000G_EUR Condel CADD_PHRED SIFT_score SIFT_pred Polyphen2_HDIV_scorePolyphen2_HDIV_pred dbSNP COSMIC_ID COSMIC_DIS ClinVar_SIG ClinVar_DIS
TP53 17 7573948 C G missense_variant 3 c.1079G>C p.Gly360Ala 0.0004 0 2 0 0.0003 0.0001 0.0002 0.001 neutral(0.002) 0.014 0.4 T 0 B rs35993958 . . unknown Hereditary_cancer-predisposing_syndrome;Hereditary_cancer-predisposing_syndrome
TP53 17 7573964 C T missense_variant 3 c.1063G>A p.Ala355Thr 0.0004 0 1 0 . . . . neutral(0.064) 13.36 0.04 D 0.003 B . . . . .
TP53 17 7577106 G A missense_variant 2 c.832C>T p.Pro278Ser 0.0003 0 1 0 . . . . deleterious(0.765) 31 0 D 1 D . COSM1646810;COSM139044;COSM3773297;COSM109393(ovary);6(large_intestine);1(urinary_tract);1(liver);1(eye);3(pancreas);9(breast);10(skin);5(oesophagus);5(upper_aerodigestive_tract);3(central_nervous_system);3(stomach);5(lung). .
TP53 17 7579485 C A stop_gained 1 c.202G>T p.Glu68Ter 0 0.0005 0 1 . . . . 0 15.2 0.78 T . . . COSM1646879;COSM131521;COSM3378370;COSM131522;COSM115135(lung);1(pancreas);5(liver). .
LRP6 12 12274102 G C missense_variant 3 c.4800C>G p.His1600Gln 0 0.0005 0 1 1.67E-05 . . . neutral(0.034) 13.25 0.03 D 0.997 D rs138902458 . . . .
LRP6 12 12277562 C T missense_variant 2 c.4484G>A p.Arg1495Gln 0.0003 0 1 0 9.06E-05 0.0001 . . deleterious(0.682) 36 0.17 T 0.999 D rs149558764 . . . .
LRP6 12 12278243 G A missense_variant 3 c.4436C>T p.Thr1479Ile 0.0016 0 5 0 0.0002 0.0003 . . neutral(0.029) 16.56 0.25 T 0.403 B rs144175121 . . . .
LRP6 12 12278309 C A missense_variant 2 c.4370G>T p.Gly1457Val 0.0003 0 1 0 4.13E-05 7.51E-05 . . deleterious(0.482) 22.9 0.25 T 0.991 D rs374072779 . . . .
LRP6 12 12279642 A G missense_variant 3 c.4295T>C p.Leu1432Ser 0.0007 0 2 0 1.65E-05 3.00E-05 . . neutral(0.013) 13.62 0.78 T 0.557 P . . . . .
LRP6 12 12279723 T A missense_variant 3 c.4214A>T p.Asp1405Val 0.0006 0.0005 2 1 3.30E-05 5.99E-05 . . neutral(0.034) 14.54 0.05 D 0.343 B . . . . .
LRP6 12 12279793 C A missense_variant 3 c.4144G>T p.Val1382Phe 0.0003 0.0017 1 3 0.0009 0.0011 0.0012 0.001 neutral(0.044) 15 0.21 T 0.04 B rs139480047 . . . .
LRP6 12 12283731 T G missense_variant 2 c.4067A>C p.Asp1356Ala 0.0003 0 1 0 1.66E-05 3.02E-05 . . deleterious(0.945) 23.1 0 D 0.998 D rs376168250 . . . .
LRP6 12 12283783 T G missense_variant 3 c.4015A>C p.Ile1339Leu 0.0003 0 1 0 . . . . neutral(0.279) 15.88 0.03 D 0.05 B . . . . .
LRP6 12 12283804 G A missense_variant 2 c.3994C>T p.Arg1332Cys 0 0.0005 0 1 6.62E-05 1.51E-05 . . deleterious(0.634) 22.4 0.02 D 0.992 D . . . . .
LRP6 12 12284815 C T missense_variant 3 c.3910G>A p.Ala1304Thr 0.0003 0 1 0 5.77E-05 5.99E-05 . . neutral(0.017) 10.9 0.58 T 0.053 B rs376223132 . . . .
LRP6 12 12284821 C T missense_variant 3 c.3904G>A p.Asp1302Asn 0 0.0006 0 1 . . . . neutral(0.461) 32 0.32 T 0.799 P . . . . .
LRP6 12 12284914 C T missense_variant 2 c.3811G>A p.Asp1271Asn 0 0.0005 0 1 . . . . deleterious(0.865) 35 0.09 T 1 D . . . . .
LRP6 12 12288226 G C missense_variant 2 c.3616C>G p.Pro1206Ala 0.0003 0 1 0 4.12E-05 6.00E-05 . . deleterious(0.476) 25.1 0.08 T 0.996 D rs373983720 . . . .
LRP6 12 12291339 T G missense_variant 3 c.3527A>C p.Glu1176Ala 0.0003 0.0011 1 2 0.0001 0.0002 . . neutral(0.005) 14.56 0.58 T 0.005 B rs145672862 . . . .
LRP6 12 12301951 T A missense_variant 2 c.3131A>T p.Asp1044Val 0.0003 0 1 0 8.24E-06 1.50E-05 . . deleterious(0.543) 20.9 0.03 D 0.838 P . . . . .
LRP6 12 12302006 G A missense_variant 2 c.3076C>T p.Arg1026Cys 0.0013 0 4 0 0.0001 0.0001 0.0008 . deleterious(0.869) 23.3 0 D 1 D rs140679529 COSM180991 1(endometrium);1(large_intestine). .
LRP6 12 12303837 T C missense_variant 3 c.2927A>G p.Asp976Gly 0.0003 0 1 0 1.65E-05 3.00E-05 . . neutral(0.050) 17.25 0.38 T 0.396 B rs368801975 . . . .
LRP6 12 12303861 C T missense_variant 3 c.2903G>A p.Arg968Gln 0.0003 0 1 0 8.24E-06 0 . . neutral(0.313) 36 0.63 T 0.999 D . . . . .
LRP6 12 12311913 C T missense_variant 2 c.2641G>A p.Val881Ile 0.0003 0 1 0 8.24E-06 1.50E-05 . . deleterious(0.790) 32 0.54 T 0.999 D . COSM1561792 1(central_nervous_system);1(large_intestine). .
LRP6 12 12311955 T C missense_variant 2 c.2599A>G p.Thr867Ala 0.0003 0.0006 1 1 0.0001 0.0002 . . deleterious(0.471) 18.01 0.37 T 0.857 P rs141458215 . . . .
LRP6 12 12315203 C T missense_variant 2 c.2203G>A p.Asp735Asn 0.0003 0 1 0 0.0001 0.0002 0.0002 0.001 deleterious(0.756) 36 0.51 T 1 D rs149258721 . . . .
LRP6 12 12315310 A C missense_variant 2 c.2096T>G p.Val699Gly 0.0003 0 1 0 . . . . deleterious(0.877) 25.4 0 D 1 D . . . . .
LRP6 12 12317322 G C missense_variant 2 c.1937C>G p.Ser646Cys 0.0003 0 1 0 . . . . deleterious(0.801) 19.86 0.04 D 1 D . . . . .
LRP6 12 12317387 C G missense_variant 3 c.1872G>C p.Met624Ile 0 0.0005 0 1 . . . . neutral(0.060) 18.58 0.17 T 0.08 B . . . . .
LRP6 12 12318150 C T missense_variant 2 c.1625G>A p.Gly542Asp 0 0.0005 0 1 8.24E-05 0.0001 . . deleterious(0.777) 26.1 0.3 T 0.999 D rs139800650 . . . .
LRP6 12 12332842 C T missense_variant 3 c.1447G>A p.Val483Ile 0.0003 0.0005 1 1 0.0162 0.0002 0.053 0.001 neutral(0.245) 17.25 0.36 T 0.013 B rs7975614 . . . .
LRP6 12 12334037 T C missense_variant 3 c.1313A>G p.Lys438Arg 0 0.0006 0 1 . . . . neutral(0.043) 13.7 0.34 T 0.091 B . . . . .
LRP6 12 12334052 T C missense_variant 2 c.1298A>G p.Asn433Ser 0 0.0005 0 1 2.47E-05 4.50E-05 . . deleterious(0.634) 19.52 0.07 T 0.982 D rs397515473 . . pathogenic Coronary_artery_disease\x2c_autosomal_dominant_2
LRP6 12 12334128 T C missense_variant 3 c.1222A>G p.Ile408Val 0.0003 0 1 0 . . . . neutral(0.261) 14.16 0.14 T 0.876 P . . . . .
LRP6 12 12334248 C T missense_variant 2 c.1102G>A p.Asp368Asn 0.0003 0 1 0 8.24E-06 1.50E-05 . . deleterious(0.798) 27.6 0.01 D 0.996 D . . . . .
LRP6 12 12334271 C T missense_variant 2 c.1079G>A p.Arg360His 0.0003 0.0011 1 1 0.0001 0.0002 . . deleterious(0.667) 33 0.13 T 1 D rs141212743 . . pathogenic Coronary_artery_disease\x2c_autosomal_dominant_2
LRP6 12 12339925 C T missense_variant 3 c.776G>A p.Arg259His 0.0003 0 1 0 4.12E-05 3.00E-05 . . neutral(0.383) 18.13 0.13 T 0.983 D . . . . .
LRP6 12 12397266 A T missense_variant 3 c.379T>A p.Ser127Thr 0.0003 0 1 0 0.002 1.50E-05 0.006 . neutral(0.000) 2.447 0.73 T 0 B rs17848270 . . . .
LRP6 12 12397530 C T missense_variant 3 c.115G>A p.Gly39Ser 0.0003 0 1 0 8.24E-05 0.0001 . . neutral(0.002) 10.42 0.74 T 0.099 B rs147654774 . . . .
LRP6 12 12397550 C T missense_variant 2 c.95G>A p.Arg32Gln 0.0003 0 1 0 . . . . deleterious(0.740) 25.2 0.07 T 0.999 D . COSM936449 1(endometrium) . .
FAN1 15 31196876 G A missense_variant 3 c.10G>A p.Glu4Lys 0 0.0005 0 1 8.38E-06 1.53E-05 . . neutral(0.064) 18.35 0.05 D 0.775 P rs369398471 . . . .
FAN1 15 31196946 C A missense_variant 3 c.80C>A p.Ser27Tyr 0.0003 0 1 0 . . . . neutral(0.406) 14.26 0.05 D 0.01 B . . . . .
FAN1 15 31196961 C T missense_variant 3 c.95C>T p.Ser32Leu 0.0006 0 2 0 3.30E-05 6.00E-05 . . neutral(0.256) 17.74 0.01 D 0.76 P . . . . .
FAN1 15 31197015 T G missense_variant 2 c.149T>G p.Met50Arg 0.0031 0.0061 10 10 0.002 0.0026 0.0018 0.006 deleterious(0.757) 22.8 0.01 D 0.999 D rs148404807 . . . .
FAN1 15 31197266 G A missense_variant 3 c.400G>A p.Val134Met 0.0003 0 1 0 4.13E-05 7.51E-05 0.0002 0.001 neutral(0.046) 9.959 0.27 T 0.471 P rs144046046 . . . .
FAN1 15 31197291 T C missense_variant 3 c.425T>C p.Leu142Pro 0 0.0005 0 1 . . . . neutral(0.035) 10.34 0.26 T 0.465 P . . . . .
FAN1 15 31197300 G A missense_variant 3 c.434G>A p.Arg145His 0.0019 0.002 6 3 0.0012 0.0018 0.0002 0.001 neutral(0.027) 10.99 0.31 T 0.025 B rs146408181 . . . .
FAN1 15 31197584 G A missense_variant 3 c.718G>A p.Glu240Lys 0.0047 0.0065 15 9 0.0035 0.0052 0.0012 0.003 neutral(0.042) 11 0.27 T 0.154 B rs150748572 . . . .
FAN1 15 31197623 C G missense_variant 3 c.757C>G p.Leu253Val 0 0.0005 0 1 . . . . neutral(0.032) 13.21 0.92 T 0.986 D . . . . .
FAN1 15 31200356 C T missense_variant 2 c.1270C>T p.Arg424Cys 0.0003 0 1 0 1.65E-05 3.00E-05 . . deleterious(0.638) 17.04 0 D 0.995 D rs368417113 . . . .
FAN1 15 31200396 A G missense_variant 3 c.1310A>G p.Glu437Gly 0.0006 0.0005 2 1 0.0041 0.0007 0.012 0.001 neutral(0.013) 7.126 0.35 T 0.008 B rs79759675 . . . .
FAN1 15 31206123 G A missense_variant 2 c.1640G>A p.Arg547His 0.0003 0 1 0 8.25E-06 1.50E-05 . . deleterious(0.892) 33 0.04 D 1 D . . . . .
FAN1 15 31210489 C G missense_variant 3 c.1934C>G p.Pro645Arg 0 0.0007 0 1 . . . . neutral(0.421) 17.92 0.3 T 0.991 D . . . . .
FAN1 15 31212765 C T missense_variant 2 c.1961C>T p.Pro654Leu 0.0006 0.0011 2 2 0.0002 0.0004 . . deleterious(0.906) 25.1 0.03 D 1 D rs144081053 . . . .
FAN1 15 31214480 T G missense_variant 2 c.2095T>G p.Tyr699Asp 0 0.0012 0 2 . . . . deleterious(0.861) 22.7 0.02 D 1 D . . . . .
FAN1 15 31214513 C T stop_gained 1 c.2128C>T p.Arg710Ter 0.0007 0 2 0 2.47E-05 1.50E-05 . . 0 42 1 T . . rs199845994 . . . .
FAN1 15 31214514 G A missense_variant 2 c.2129G>A p.Arg710Gln 0.0003 0 1 0 1.65E-05 . . . deleterious(0.843) 35 0 D 1 D . . . . .
FAN1 15 31221509 G A missense_variant 3 c.2696G>A p.Arg899Gln 0.0004 0.0006 1 0 2.47E-05 4.50E-05 . . neutral(0.010) 2.025 0.64 T 0.273 B . . . . .
FAN1 15 31221566 G A missense_variant 3 c.2753G>A p.Ser918Asn 0.0004 0.0006 1 0 1.65E-05 3.00E-05 . . neutral(0.038) 12.69 1 T 0.107 B . . . . .
FAN1 15 31222830 C T missense_variant 2 c.2872C>T p.Leu958Phe 0 0.0006 0 1 8.27E-06 1.50E-05 0.0002 0.001 deleterious(0.506) 20.5 0.15 T 0.997 D rs147984615 . . . .
FANCM 14 45605302 C A missense_variant 3 c.68C>A p.Pro23Gln 0 0.0005 0 1 1.69E-05 3.09E-05 . . neutral(0.043) 15.42 0.2 T 0.929 P rs377031191 . . . .
FANCM 14 45605336 C A missense_variant 3 c.102C>A p.Ser34Arg 0.0003 0 1 0 . . . . neutral(0.174) 20.5 0.08 T 0.838 P . . . . .
FANCM 14 45605397 G A missense_variant 2 c.163G>A p.Asp55Asn 0.0006 0.0016 2 2 0.0004 0.0008 . . deleterious(0.649) 35 0.02 D 0.993 D rs148017562 COSM3718474 1(upper_aerodigestive_tract). .
FANCM 14 45605405 G C missense_variant 3 c.171G>C p.Leu57Phe 0.0029 0.0064 9 10 0.0016 0.0025 0.0004 0.002 neutral(0.414) 15.37 0.16 T 0.078 B rs142007602 . . . .
FANCM 14 45605503 C T missense_variant 2 c.269C>T p.Pro90Leu 0.0013 0 4 0 0.0002 0.0004 . . deleterious(0.757) 29.1 0 D 0.916 P rs142904668 . . . .
FANCM 14 45606290 C T missense_variant 3 c.527C>T p.Thr176Ile 0.0032 0.0041 10 7 0.0044 0.0056 0.0014 0.005 neutral(0.050) 10.31 0.22 T 0.003 B rs77374493 . . . .
FANCM 14 45618149 T C missense_variant 3 c.869T>C p.Ile290Thr 0 0.0005 0 1 4.97E-05 9.03E-05 . . neutral(0.449) 15.03 0.04 D 0.147 B rs377303950 . . . .
FANCM 14 45618154 C A missense_variant 2 c.874C>A p.Pro292Thr 0 0.0006 0 1 . . . . deleterious(0.747) 18.46 0.01 D 0.896 P . . . . .
FANCM 14 45618161 G A missense_variant 2 c.881G>A p.Gly294Asp 0.0003 0 1 0 . . . . deleterious(0.509) 18.3 0.02 D 0.212 B . . . . .
FANCM 14 45623953 T C missense_variant 2 c.1237T>C p.Tyr413His 0.0023 0.0005 7 1 0.0008 0.0012 0.0002 . deleterious(0.789) 18.7 0.05 D 0.966 D rs138225703 . . . .
FANCM 14 45624629 G A missense_variant 2 c.1363G>A p.Glu455Lys 0 0.0005 0 1 . . . . deleterious(0.698) 28 0.07 T 0.753 P . . . . .
FANCM 14 45628364 A G missense_variant 2 c.1462A>G p.Ser488Gly 0.0006 0 2 0 2.56E-05 4.69E-05 . . deleterious(0.902) 24 0.01 D 0.819 P rs374988842 . . . .
FANCM 14 45628452 C T missense_variant 3 c.1550C>T p.Thr517Met 0.0003 0.0006 1 1 3.33E-05 4.55E-05 . . neutral(0.024) 10.89 0.29 T 0.165 B . . . . .
FANCM 14 45633577 C T missense_variant 2 c.1597C>T p.Arg533Cys 0 0.0006 0 1 0.0004 0.0006 . . deleterious(0.592) 27.9 0 D 0.991 D rs146151355 COSM1721918 2(NS) . .
FANCM 14 45633616 G A missense_variant 2 c.1636G>A p.Gly546Ser 0 0.0005 0 1 4.95E-05 7.50E-05 . . deleterious(0.935) 36 0.01 D 1 D . . . . .
FANCM 14 45636337 G A missense_variant 3 c.1973G>A p.Arg658Gln 0.0003 0 1 0 8.28E-06 1.50E-05 . . neutral(0.297) 16.19 0.3 T 0.944 P . . . . .
FANCM 14 45639927 T C missense_variant 2 c.2138T>C p.Leu713Ser 0.0004 0 1 0 . . . . deleterious(0.794) 11.11 0.02 D 0.985 D . . . . .
FANCM 14 45642333 A G missense_variant 2 c.2236A>G p.Thr746Ala 0 0.0005 0 1 8.24E-06 1.50E-05 . . deleterious(0.585) 14.04 0.09 T 0.819 P . . . . .
FANCM 14 45642358 G A missense_variant 2 c.2261G>A p.Arg754Gln 0.0003 0 1 0 1.65E-05 1.50E-05 0.0002 . deleterious(0.884) 33 0.04 D 1 D rs529256568 . . . .
FANCM 14 45644346 C G missense_variant 3 c.2389C>G p.Pro797Ala 0.0003 0.0005 1 1 8.26E-06 1.50E-05 . . neutral(0.002) 0.056 0.7 T 0.031 B rs144771929 . . . .
FANCM 14 45644458 A G missense_variant 2 c.2501A>G p.Glu834Gly 0.0006 0 2 0 . . . . deleterious(0.715) 14.72 0.01 D 0.979 D . . . . .
FANCM 14 45644709 A G missense_variant 3 c.2752A>G p.Lys918Glu 0.0003 0 1 0 2.48E-05 4.51E-05 . . neutral(0.000) 0 0.86 T 0 B . . . . .
FANCM 14 45644816 A C missense_variant 2 c.2859A>C p.Lys953Asn 0.0031 0.0031 9 5 0.0011 0.0018 . . deleterious(0.688) 14.93 0.05 D 0.999 D rs142864437 . . . .
FANCM 14 45645144 A G missense_variant 3 c.3187A>G p.Lys1063Glu 0.0003 0 1 0 . . . . neutral(0.060) 7.373 0.1 T 0.421 B . . . . .
FANCM 14 45645150 T G missense_variant 3 c.3193T>G p.Cys1065Gly 0.0003 0 1 0 . . 0.0002 . neutral(0.301) 2.486 0.03 D 0.267 B rs201836469 . . . .
FANCM 14 45645433 T C missense_variant 3 c.3476T>C p.Leu1159Ser 0.0003 0 1 0 . . . . neutral(0.001) 0.007 0.74 T 0.013 B . . . . .
FANCM 14 45645661 G T missense_variant 2 c.3704G>T p.Gly1235Val 0 0.0005 0 1 8.30E-06 1.51E-05 . . deleterious(0.935) 18.79 0 D 1 D rs146490925 . . . .
FANCM 14 45645702 A G missense_variant 3 c.3745A>G p.Thr1249Ala 0.0003 0 1 0 . . . . neutral(0.000) 0.004 0.91 T 0 B . COSM553235 1(lung) . .
FANCM 14 45645784 C T missense_variant 3 c.3827C>T p.Ser1276Leu 0 0.0005 0 1 6.70E-05 4.54E-05 . . neutral(0.002) 0.061 0.41 T 0.004 B . COSM275090 1(large_intestine) . .
FANCM 14 45645826 C T missense_variant 3 c.3869C>T p.Thr1290Ile 0.0003 0 1 0 2.48E-05 4.51E-05 . . neutral(0.056) 3.131 0.27 T 0.002 B . . . . .
FANCM 14 45645855 G T stop_gained 1 c.3898G>T p.Glu1300Ter 0 0.0005 0 1 . . . . 0 12.64 0.78 T . . . . . . .
FANCM 14 45645864 C A missense_variant 3 c.3907C>A p.Gln1303Lys 0.0003 0 1 0 8.25E-06 1.50E-05 . . neutral(0.009) 2.981 0.32 T 0.483 P rs369549739 . . . .
FANCM 14 45645949 C T missense_variant 3 c.3992C>T p.Pro1331Leu 0 0.0005 0 1 0.0001 0.0002 . . neutral(0.420) 11.32 0.03 D 0.289 B rs149348098 . . . .
FANCM 14 45645955 A C missense_variant 3 c.3998A>C p.Gln1333Pro 0.0006 0.0005 2 1 9.20E-05 0.0002 . . neutral(0.038) 2.52 0.2 T 0.022 B rs143681767 . . . .
FANCM 14 45645978 C G missense_variant 3 c.4021C>G p.Leu1341Val 0 0.0005 0 1 . . . . neutral(0.343) 10.39 0.3 T 0.996 D . . . . .
FANCM 14 45646041 G A missense_variant 3 c.4084G>A p.Asp1362Asn 0.0003 0 1 0 0.0002 0.0002 . . neutral(0.198) 12.61 0.45 T 0.915 P rs199895244 . . . .
FANCM 14 45650888 C T missense_variant 3 c.4366C>T p.Arg1456Cys 0.0003 0.0005 1 1 0.0002 0.0003 . . neutral(0.261) 12.08 0.16 T 0.032 B rs200360968 . . . .
FANCM 14 45658342 A C missense_variant 3 c.5117A>C p.Asn1706Thr 0 0.0005 0 1 2.48E-05 3.01E-05 . . neutral(0.003) 1.321 0.77 T 0.008 B . . . . .
FANCM 14 45658402 C T missense_variant 3 c.5177C>T p.Pro1726Leu 0.0003 0.0005 1 1 4.12E-05 6.00E-05 . . neutral(0.021) 9.94 0.18 T 0.039 B . . . . .
FANCM 14 45665603 G A missense_variant 2 c.5569G>A p.Val1857Met 0.0006 0.0017 2 3 0.0004 0.0005 0.0008 0.001 deleterious(0.935) 19.52 0 D 1 D rs144008013 . . . .
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FANCM 14 45665613 G A missense_variant 2 c.5579G>A p.Arg1860His 0.0003 0 1 0 2.47E-05 4.50E-05 . . deleterious(0.935) 26.4 0 D 1 D . COSM955827 1(large_intestine);1(endometrium). .
FANCM 14 45665637 A G missense_variant 2 c.5603A>G p.Gln1868Arg 0 0.0005 0 1 1.65E-05 1.50E-05 . . deleterious(0.752) 16.69 0 D 0.999 D . . . . .
FANCM 14 45667921 C T stop_gained 1 c.5791C>T p.Arg1931Ter 0.0003 0.0021 1 4 0.0009 0.0009 0.0006 0.003 0 40 1 T . . rs144567652 . . . .
FANCM 14 45669207 T C missense_variant 3 c.6143T>C p.Ile2048Thr 0.0003 0.0005 1 1 3.31E-05 6.02E-05 . . neutral(0.453) 10.92 0 D 0 B rs150447576 . . . .
RPS20 8 56986271 C G missense_variant 2 c.160G>C p.Val54Leu 0 0.0005 0 1 8.24E-06 1.50E-05 . . deleterious(0.760) 19.8 0 D 0.99 D . . . . .
PTPN12 7 77240335 A G missense_variant 3 c.911N>G p.His304Arg 0 0.0005 0 1 0.0001 0.0002 . . neutral(0.023) 10.98 0.41 T 0 B rs200238133 . . . .
PTPN12 7 77256177 A G missense_variant 2 c.1181N>G p.His394Arg 0.0003 0 1 0 . . . . deleterious(0.799) 21 0.78 T 0.999 D . . . . .
PTPN12 7 77256234 C T missense_variant 3 c.1238N>T p.Thr413Ile 0 0.0005 0 1 . . . . neutral(0.299) 9.173 0.01 D 0.04 B . . . . .
PTPN12 7 77256365 A C missense_variant 2 c.1369N>C p.Asn457His 0 0.001 0 2 1.66E-05 3.01E-05 . . deleterious(0.716) 17.21 0.04 D 0.97 D rs145330429 . . . .
PTPN12 7 77256375 A G missense_variant 3 c.1379N>G p.His460Arg 0.0003 0 1 0 . . . . neutral(0.378) 17.85 0.08 T 0.99 D . . . . .
PTPN12 7 77256453 A G missense_variant 3 c.1457N>G p.Asn486Ser 0.0003 0 1 0 . . . . neutral(0.001) 0.003 0.89 T 0.002 B . . . . .
PTPN12 7 77256502 A T missense_variant 3 c.1506N>T p.Gln502His 0 0.0011 0 2 3.30E-05 6.00E-05 . . neutral(0.249) 3.617 0.3 T 0.001 B . . . . .
PTPN12 7 77256528 C T missense_variant 3 c.1532N>T p.Pro511Leu 0.0003 0 1 0 . . . . neutral(0.025) 0.64 0.67 T 0.007 B . . . . .
PTPN12 7 77256562 G T missense_variant 2 c.1566N>T p.Arg522Ser 0 0.0005 0 1 . . . . deleterious(0.771) 19.04 0.1 T 0.999 D rs374516234 . . . .
PTPN12 7 77256600 C T missense_variant 3 c.1604N>T p.Thr535Met 0 0.0005 0 1 8.24E-06 1.50E-05 . . neutral(0.032) 5.044 0.23 T 0.004 B . . . . .
PTPN12 7 77256672 A G missense_variant 3 c.1676N>G p.Asn559Ser 0 0.0005 0 1 3.30E-05 1.50E-05 . . neutral(0.011) 0.015 0.85 T 0.001 B rs61757751 . . . .
PTPN12 7 77256872 A G missense_variant 2 c.1876N>G p.Thr626Ala 0.0003 0 1 0 8.25E-06 1.50E-05 . . deleterious(0.853) 20.5 0.01 D 0.999 D . . . . .
PTPN12 7 77261719 C T missense_variant 2 c.2051N>T p.Ser684Leu 0.0006 0.0015 2 3 0.0009 0.0012 . . deleterious(0.889) 26.8 0 D 1 D rs201001953 . . . .
PTPN12 7 77267946 C G missense_variant 3 c.2179N>G p.Pro727Ala 0.0003 0 1 0 . . . . neutral(0.001) 1.863 0.97 T 0.104 B . . . . .
PTPN12 7 77256690 CTG C frameshift_variant 1 c.1695_1696delTG p.Val566GlufsTer11 0.0003 0 1 0 0 35
BUB1 2 111397347 C G missense_variant 3 c.3034G>C p.Glu1012Gln 0 0.0005 0 1 . . . . neutral(0.447) 14.39 0.69 T 0.026 B . . . . .
BUB1 2 111397415 A G missense_variant 2 c.2966T>C p.Phe989Ser 0.0003 0 1 0 . . . . deleterious(0.906) 18.63 0.01 D 1 D . . . . .
BUB1 2 111398700 A G missense_variant 2 c.2866T>C p.Phe956Leu 0.0003 0 1 0 . . . . deleterious(0.911) 29.6 0.33 T 1 D . . . . .
BUB1 2 111406857 C T stop_gained 1 c.2301G>A p.Trp767Ter 0.0006 0 2 0 1.65E-05 3.00E-05 0.0002 0.001 0 39 0.24 T . . rs201494812 . . untested Malignant_melanoma
BUB1 2 111406882 C T missense_variant 3 c.2276G>A p.Ser759Asn 0 0.0005 0 1 6.60E-05 0.0001 0.0002 . neutral(0.005) 11.01 0.26 T 0.036 B rs182377124 . . . .
BUB1 2 111406904 A G missense_variant 2 c.2254T>C p.Ser752Pro 0.0003 0 1 0 8.26E-06 1.50E-05 . . deleterious(0.892) 19.64 0.17 T 1 D . . . . .
BUB1 2 111408213 C T missense_variant 3 c.2113G>A p.Ala705Thr 0.0003 0 1 0 1.66E-05 1.50E-05 . . neutral(0.015) 9.661 0.7 T 0.002 B . . . . .
BUB1 2 111414668 G A missense_variant 3 c.1643C>T p.Thr548Ile 0.0006 0.0005 2 1 3.30E-05 4.50E-05 . . neutral(0.020) 7.683 0.24 T 0.001 B rs376146753 . . . .
BUB1 2 111416221 A T missense_variant 2 c.1375T>A p.Ser459Thr 0 0.0005 0 1 1.65E-05 3.00E-05 . . deleterious(0.919) 26.2 0.37 T 1 D . . . . .
BUB1 2 111416229 A G missense_variant 3 c.1367T>C p.Val456Ala 0 0.0005 0 1 3.30E-05 4.50E-05 0.0002 . neutral(0.311) 16.19 0.38 T 0.818 P rs531352750 . . . .
BUB1 2 111419297 G T missense_variant 2 c.1079C>A p.Pro360His 0.0003 0 1 0 . . . . deleterious(0.616) 16.32 0.55 T 0.997 D . . . . .
BUB1 2 111419307 C T missense_variant 3 c.1069G>A p.Glu357Lys 0.0007 0 2 0 2.48E-05 3.01E-05 . . neutral(0.001) 3.291 0.79 T 0 B . . . . .
BUB1 2 111425226 G A missense_variant 3 c.677C>T p.Ala226Val 0.0044 0.0065 14 12 0.0019 0.0028 0.0012 0.006 neutral(0.409) 21.2 0.44 T 0.901 P rs61730706 . . . .
BUB1 2 111425402 A G missense_variant 3 c.592T>C p.Ser198Pro 0.0003 0 1 0 . . . . neutral(0.059) 12.33 0.33 T 0.01 B . . . . .
BUB1 2 111430329 C T missense_variant 3 c.331G>A p.Ala111Thr 0.0003 0 1 0 . . . . neutral(0.003) 7.02 0.58 T 0.128 B . . . . .
BUB1 2 111430340 C T missense_variant 3 c.320G>A p.Gly107Glu 0 0.0006 0 1 4.95E-05 9.00E-05 . . neutral(0.001) 0.008 0.36 T 0.052 B rs369472330 . . . .
BUB1 2 111430353 T C missense_variant 3 c.307A>G p.Ile103Val 0.0003 0 1 0 8.25E-05 3.00E-05 0.0002 . neutral(0.005) 6.817 1 T 0 B rs376910351 . . . .
BUB3 10 124920001 A G missense_variant 2 c.496A>G p.Asn166Asp 0.0003 0 1 0 . . . . deleterious(0.753) 33 0.1 T 0.99 D . . . . .
BUB3 10 124921765 G T missense_variant 2 c.590G>T p.Ser197Ile 0.0003 0 1 0 . . . . deleterious(0.850) 26.6 0 D 1 D . . . . .
BUB3 10 124921827 A T stop_gained 1 c.652A>T p.Lys218Ter 0.0006 0 2 0 . . . . 0 37 1 T . . . . . . .
BUB3 10 124922242 C T missense_variant 3 c.869C>T p.Thr290Met 0 0.0005 0 1 1.65E-05 0 . . neutral(0.029) 8.721 0.2 T 0.008 B rs151202304 . . . .
BUB3 10 124922274 A G missense_variant 3 c.901A>G p.Met301Val 0.0003 0 1 0 2.47E-05 4.50E-05 . . neutral(0.034) 5.416 0.16 T 0.005 B rs140277834 . . . .
RPS20 8 56985826 CAA C frameshift_variant 1 c.181_182delTT p.Leu61GlufsTer11 0 0.0005 0 1 0 25
BUB1 2 111415994 CTG C frameshift_variant 1 c.1507_1508delCA p.Gln503ValfsTer15 0.0003 0 1 0 0 37
BUB1 2 111427085 ATT A frameshift_variant 1 c.510_511delAA p.Gln170HisfsTer11 0.0003 0 1 0 8.24E-06 0 . . 0 22 . . . . . . . . .
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Supplementary Figure 1: Forest plot of allelic odds ratio associated with FANCM 
p.Arg1931Ter (rs144567652) genotype and CRC.  Studies [SMITH: original publication (2,207 
cases, 2,176 controls)
1
; WES: whole-exome sequencing analyzed in this manuscript (863 
cases, 1,604 controls); ENG: English Illumina Exome-BeadChip replication series (3,537 
cases, 4,811 controls); SCOT: Scottish Illumina Exome-BeadChip replication series (2,015 
cases, 1,981 controls)] were weighted according to the inverse of the variance of the log of 
the odds ratio (OR) calculated by unconditional logistic regression. Meta-analysis under a 
fixed-effects model was conducted using standard methods. Cochran’s Q statistic to test for 
heterogeneity and the I
2
 statistic to quantify the proportion of the total variation due to 
heterogeneity were calculated. Horizontal lines indicate 95% confidence intervals (CIs). 
Boxes indicate OR point estimate; its area is proportional to the weight of the study. 
Diamond (and broken line) indicates overall summary estimate, with CI given by its width. 
Unbroken vertical line indicates null value (OR=1.0). 
Meta P=0.22 
